Aclaris Therapeutics (ACRS) said Tuesday it has obtained clearance to proceed with a phase 1a/1b clinical trial of its monoclonal antibody ATI-052, which is being developed to treat certain immuno-inflammatory diseases, from the US Food and Drug Administration.
The clinical trial will assess single and multiple ascending doses of ATI-052, followed by a proof-of-concept portion in an undisclosed indication, the company said.
Aclaris said it expects to start the trial in Q2.
Price: 1.14, Change: +0.01, Percent Change: +0.88
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.